Laurion Capital Management LP Viracta Therapeutics, Inc. Transaction History
Laurion Capital Management LP
- $8.4 Billion
- Q2 2024
A detailed history of Laurion Capital Management LP transactions in Viracta Therapeutics, Inc. stock. As of the latest transaction made, Laurion Capital Management LP holds 407,299 shares of VIRX stock, worth $81,459. This represents 0.0% of its overall portfolio holdings.
Number of Shares
407,299
Previous 420,426
3.12%
Holding current value
$81,459
Previous $428,000
48.83%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding VIRX
# of Institutions
45Shares Held
9.04MCall Options Held
10.9KPut Options Held
400-
Bvf Inc San Francisco, CA3.61MShares$722,9320.06% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.52MShares$304,0480.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.16MShares$232,2560.0% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA690KShares$137,9410.19% of portfolio
-
Aisling Capital Management LP New York, NY289KShares$57,7140.07% of portfolio
About Viracta Therapeutics, Inc.
- Ticker VIRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,558,200
- Market Cap $7.51M
- Description
- Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket tr...